Dizon DS - Search Results

1

Advances in the management of recurrent endometrial cancer.

Bradford LS, Rauh-Hain JA, Schorge J, Birrer MJ, Dizon DS. Bradford LS, et al. Among authors: dizon ds. Am J Clin Oncol. 2015 Apr;38(2):206-12. doi: 10.1097/COC.0b013e31829a2974. Am J Clin Oncol. 2015. PMID: 23764681 Review.

2

Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.

Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, Venkatraman E, Spriggs DR. Dizon DS, et al. J Clin Oncol. 2002 Mar 1;20(5):1238-47. doi: 10.1200/JCO.2002.20.5.1238. J Clin Oncol. 2002. PMID: 11870166

3

Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.

Dizon DS, Dupont J, Anderson S, Sabbatini P, Hummer A, Aghajanian C, Spriggs D. Dizon DS, et al. Gynecol Oncol. 2003 Dec;91(3):584-90. doi: 10.1016/j.ygyno.2003.08.017. Gynecol Oncol. 2003. PMID: 14675681

4

Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Sabbatini P, Aghajanian C, Dizon D, Anderson S, Dupont J, Brown JV, Peters WA, Jacobs A, Mehdi A, Rivkin S, Eisenfeld AJ, Spriggs D. Sabbatini P, et al. J Clin Oncol. 2004 Nov 15;22(22):4523-31. doi: 10.1200/JCO.2004.12.043. J Clin Oncol. 2004. PMID: 15542803 Clinical Trial.

5

Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer.

Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR. Aghajanian C, et al. Among authors: dizon ds. J Clin Oncol. 2005 Sep 1;23(25):5943-9. doi: 10.1200/JCO.2005.16.006. J Clin Oncol. 2005. PMID: 16135465 Clinical Trial.

6

For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?

Dizon DS, Restivo A, Lomme M, Charbonneau N, Brard L, Hughes T, Weitzen S, Legare R, Granai CO, Disilvestro P. Dizon DS, et al. Am J Clin Oncol. 2008 Feb;31(1):39-42. doi: 10.1097/COC.0b013e318134ee6f. Am J Clin Oncol. 2008. PMID: 18376226

7

Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer?

McCourt C, Dessie S, Bradley AM, Schwartz J, Brard L, Dizon DS. McCourt C, et al. Among authors: dizon ds. Int J Gynecol Cancer. 2009 Apr;19(3):343-7. doi: 10.1111/IGC.0b013e3181a12eb9. Int J Gynecol Cancer. 2009. PMID: 19407557

8

Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.

Dizon DS, Blessing JA, McMeekin DS, Sharma SK, Disilvestro P, Alvarez RD. Dizon DS, et al. J Clin Oncol. 2009 Jul 1;27(19):3104-8. doi: 10.1200/JCO.2008.20.6995. Epub 2009 May 18. J Clin Oncol. 2009. PMID: 19451430 Free PMC article. Clinical Trial.

9

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.

Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Penson RT, et al. Among authors: dizon ds. J Clin Oncol. 2010 Jan 1;28(1):154-9. doi: 10.1200/JCO.2009.22.7900. Epub 2009 Nov 16. J Clin Oncol. 2010. PMID: 19917843 Clinical Trial.

10

Treatment options for advanced endometrial carcinoma.

Dizon DS. Dizon DS. Gynecol Oncol. 2010 May;117(2):373-81. doi: 10.1016/j.ygyno.2010.02.007. Epub 2010 Mar 12. Gynecol Oncol. 2010. PMID: 20223510 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

239 results

Search Page

Filters